Community viral load as a measure for assessment of HIV treatment as prevention

The Lancet Infectious Diseases

Volumn 13, Issue 5, 2013, Pages 459-464

  Miller, William C ^a   Powers, Kimberly A ^a   Smith, M Kumi ^a   Cohen, Myron S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMMUNITY VIRAL LOAD; DISEASE TRANSMISSION; ECOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NOTE; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; SAMPLE SIZE; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DATABASES, FACTUAL; DISEASE TRANSMISSION, INFECTIOUS; HIV; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE; PREVALENCE; SEXUAL BEHAVIOR; TIME FACTORS; VIRAL LOAD;

EID: 84876729911     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70314-6     Document Type: Note

References (37)

1. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010, 5:e11068.
2. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010, 376:532-539.
3. Castel AD, Befus M, Willis S, et al. Use of the community viral load as a population-based biomarker of HIV burden. AIDS 2012, 26:345-353.
4. Wood E, Kerr T, Marshall BD, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009, 338:b1649.
5. Jain V, Liegler T, Chamie G, et al. Assessment of community viral load using a fingerprick-based blood collection method: Uganda. 19th Conference on Retroviruses and Opportunistic Infections; Seattle, WA; March 5-8, 2012. 143LB.
6. Henard S, Jeanmaire E, Nguyen Y, et al. Is total community viral load a robust predictive marker of the efficacy of the TasP strategy?. J Acquir Immune Defic Syndr 2012, 61:600-602.
7. Smith MK, Powers KA, Muessig KE, Miller WC, Cohen MS HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med 2012, 9:e1001260.
8. Seek, test, treat, and retain: addressing HIV among vulnerable populations (R01) National Institutes of Health, (accessed May 31, 2012). http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-11-001.html.
9. Using viral load data to monitor HIV burden and treatment outcomes in the United States Centers for Disease Control and Prevention, (accessed May 31, 2012). http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/viral_load.htm.
10. Guidance on community viral load: a family of measures, definitions, and method for calculation Centers for Disease Control and Prevention, (accessed May 31, 2012). http://www.ct.gov/dph/lib/dph/aids_and_chronic/surveillance/statewide/community_viralload_guidance.pdf.
11. The White House National HIV/AIDS Strategy for the United States, July 2010 (accessed May 31, 2012). http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf.
12. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ Applying public health principles to the HIV epidemic. N Engl J Med 2005, 353:2397-2402.
13. Shelton JD, Cohen M, Barnhart M, Hallett T Is antiretroviral therapy modifying the HIV epidemic?. Lancet 2010, 376:1824-1825.
14. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800.
15. Burns DN, Dieffenbach CW, Vermund SH Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010, 51:725-731.
16. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep 2011, 60:1618-1623. Centers for Disease Control and Prevention.
17. Fiscus SA, Pilcher CD, Miller WC, et al. Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007, 195:416-424.
18. Patel P, Klausner JD, Bacon OM, et al. Detection of acute HIV infections in high-risk patients in California. J Acquir Immune Defic Syndr 2006, 42:75-79.
19. Pilcher CD, Fiscus SA, Nguyen TQ, et al. Detection of acute infections during HIV testing in North Carolina. N Engl J Med 2005, 352:1873-1883.
20. Priddy FH, Pilcher CD, Moore RH, et al. Detection of acute HIV infections in an urban HIV counseling and testing population in the United States. J Acquir Immune Defic Syndr 2007, 44:196-202.
21. Kelley CF, Barbour JD, Hecht FM The relation between symptoms, viral load, and viral load set point in primary HIV infection. J Acquir Immune Defic Syndr 2007, 45:445-448.
22. Hollingsworth TD, Anderson RM, Fraser C HIV-1 transmission, by stage of infection. J Infect Dis 2008, 198:687-693.
23. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879.
24. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007, 21:1723-1730.
25. Ma ZM, Stone M, Piatak M, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009, 83:3288-3297.
26. Cohen MS, Shaw GM, McMichael AJ, Haynes BF Acute HIV-1 infection. N Engl J Med 2011, 364:1943-1954.
27. Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011, 378:256-268.
28. Percus JK, Percus OE, Di Mascio M The amplitudes of viral blips in HIV-1 infected patients treated with antiretroviral therapy are power-law distributed. J Theor Biol 2009, 257:454-459.
29. Hull MW, Lima VD, Hogg RS, Harrigan PR, Montaner JS Epidemiology of treatment failure: a focus on recent trends. Curr Opin HIV AIDS 2009, 4:467-473.
30. Rothman KJ, Greenland S, Lash TL Modern epidemiology 2008, Lippincott Williams & Wilkins, Philadelphia, PA. 3rd edn.
31. Chu H, Gange SJ, Li X, et al. The effect of HAART on HIV RNA trajectory among treatment-naïve men and women: a segmental Bernoulli/lognormal random effects model with left censoring. Epidemiology 2010, 21(suppl 4):S25-S34.
32. Doherty IA, Padian NS, Marlow C, Aral SO Determinants and consequences of sexual networks as they affect the spread of sexually transmitted infections. J Infect Dis 2005, 191(suppl 1):S42-S54.
33. Reniers G, Watkins S Polygyny and the spread of HIV in sub-Saharan Africa: a case of benign concurrency. AIDS 2010, 24:299-307.
34. Koopman JS, Longini IM The ecological effects of individual exposures and nonlinear disease dynamics in populations. Am J Public Health 1994, 84:836-842.
35. Kerr T, Small W, Buchner C, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health 2010, 100:1449-1453.
36. Kerr T, Tyndall M, Li K, Montaner J, Wood E Safer injection facility use and syringe sharing in injection drug users. Lancet 2005, 366:316-318.
37. Kelley CF, Rosenberg ES, O'Hara BM, et al. Measuring population transmission risk for HIV: an alternative metric of exposure risk in men who have sex with men (MSM) in the USA. PLoS One 2012, 7:e53284.